Pentoxifylline in Diabetic Kidney Disease

Summary

Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.

Timeline

Start

2019-11-18

Primary completion

2028-01-03

Completion

2030-07-08

Publications

• Kononowech J, Ranusch A, Sales AE. Anticipating implementation: A mixed methods study of future prescribing determinants within an ongoing trial of clinical effectiveness. Implement Sci Commun. 2026 May 29. doi: 10.1186/s43058-026-00969-0. Online ahead of print.
• Colombijn JM, Hooft L, Jun M, Webster AC, Bots ML, Verhaar MC, Vernooij RW. Antioxidants for adults with chronic kidney disease. Cochrane Database Syst Rev. 2023 Nov 2;11(11):CD008176. doi: 10.1002/14651858.CD008176.pub3.
• Leehey DJ, Carlson K, Reda DJ, Craig I, Clise C, Conner TA, Agarwal R, Kaufman JS, Anderson RJ, Lammie D, Huminik J, Polzin L, McBurney C, Huang GD, Emanuele NV. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial. BMJ Open. 2021 Aug 16;11(8):e053019. doi: 10.1136/bmjopen-2021-053019.

Drugs

Indications